Aerie Pharmaceuticals Stock News

Aerie (AERI) delivered earnings and revenue surprises of 35.71% and 2.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Here are four top-ranked liquid stocks, Oxford Industries (OXM), Aerie Pharmaceuticals (AERI), Perion Network (PERI), and Pure Storage (PSTG), which investors can add to their portfolio for returns.

We have narrowed our search to five small cap stocks that have provided more than 35% returns year to date,These are: AERI, AMAL, RELL, PHX and SBOW.

Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.

Here is how Aerie Pharmaceuticals (AERI) and Mersana Therapeutics, Inc. (MRSN) have performed compared to their sector so far this year.

Here is how Aerie Pharmaceuticals (AERI) and Hanger (HNGR) have performed compared to their sector so far this year.

Here is how Aerie Pharmaceuticals (AERI) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.

Here is how Aerie Pharmaceuticals (AERI) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

You'd vault skyward, too, if a big-pocketed company were willing to spend a lot of coin on acquiring you.

Most investors would probably be pleased with a share price gain of 33% in just over three years, but more than 50% sounds a lot better.

Aerie (AERI) enters into an agreement with Alcon to be acquired for $770 million. Shares gain.

Alcon agrees to acquire Aerie, the ophthalmic therapies company, for $15.25 a share.

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Hans Vitzthum – Investor Relations Raj Kannan – Chief Executive Officer P

Aerie (AERI) Q2 loss narrows year over year and revenues beat estimates in the second quarter of 2022.